Yang Mulligan

Yang Mulligan, CFA, is an accomplished finance director specializing in global oncology new assets within the pharmaceutical industry. They bring a track record of success in valuing biopharmaceutical assets and have played pivotal roles in mergers, acquisitions, and licensing, particularly during the ORGANON spin-off from Merck. With exceptional analytical skills and a results-focused approach, Yang has led significant commercial assessments and developed innovative forecasting models to improve business strategies. Currently pursuing further education at Huazhong University of Science and Technology and the London School of Economics, Yang holds an MBA from Rutgers Business School.